Childhood Hemolytic Uremic Syndrome, United Kingdom and Ireland
Richard M. Lynn*, Sarah J. O’Brien†
1
, C. Mark Taylor‡, Goutam K. Adak†, Henrik Chart§, Tom Cheasty§, John E. Coia¶, Iain A. Gillespie†, Mary E. Locking#, William J. Reilly#, Henry R. Smith§, Aoife Waters**, and Geraldine A. Willshaw§
Author affiliations: *Royal College of Paediatrics and Child Health, London, United Kingdom; †Communicable Disease Surveillance Centre, London, United Kingdom; ‡Birmingham Children’s Hospital, Birmingham, United Kingdom; §Health Protection Agency Centre for Infections, London, United Kingdom; ¶Western General Hospital, Edinburgh, United Kingdom; #Scottish Centre for Infection and Environmental Health, Glasgow, United Kingdom; and; **The Children’s Hospital, Dublin, Ireland
Main Article
Table 2
Clinical features and acute complications of diarrhea-associated hemolytic uremic syndrome (HUS) in children from the 1997–2001 British Paediatric Surveillance Unit survey compared with children from the 1985–1988 survey
|
1985–1988 survey |
1997–2001 survey |
p value |
No. of cases |
288 |
413 |
|
Cases with a diarrheal prodrome |
273 (95%) |
395 (96%) |
0.6 |
Mean (range) time from onset of diarrhea to diagnosis of HUS |
8 days (1–34) |
6 days (range 1–35) |
<0.001 |
Severe acute abdominal symptoms |
40 (15%) |
36 (9%) |
0.03 |
Seizures or other neurologic complications |
51(19%) |
52 (13%) |
0.06 |
Hypertension |
86 (32%) |
92 (23%) |
0.02 |
Cardiomyopathy |
4 (1%) |
7 (2%) |
1.0 |
Diabetes mellitus |
4 (1%) |
8 (2%) |
0.77 |
Main Article
Page created: May 23, 2011
Page updated: May 23, 2011
Page reviewed: May 23, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.